Publication Name	World Journal of Clinical Cases
Manuscript ID	78099
Country	China

Received	2022-06-23 12:30
Peer-Review Started	2022-06-23 12:34
To Make the First Decision
Return for Revision	2022-08-22 03:03
Revised	2022-09-01 15:10
Second Decision	2022-10-17 03:30
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-10-17 07:11
Articles in Press	2022-10-17 07:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2022-10-27 15:32
Publish the Manuscript Online	2022-11-08 07:44

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature
Manuscript Source	Unsolicited Manuscript
All Author List	Meng-Ye He, Fei-Fei Yan, Kai-Li Cen and Peng Shen
ORCID	Author(s) ORCID Number Meng-Ye He http://orcid.org/0000-0003-3342-3723 Fei-Fei Yan http://orcid.org/0000-0001-5003-096X Peng Shen http://orcid.org/0000-0002-1123-9848
Funding Agency and Grant Number
Corresponding Author	Meng-Ye He, MD, Doctor, Medical oncology, First affiliated hospital,Zhejiang University school of medicine, No.79 Qingchun Road, Hangzhou 310000, Zhejiang Province, China. 1511051@zju.edu.cn
Key Words	Intrahepatic cholangiocarcinoma; Programmed cell death protein-1 inhibitor; Paclitaxel; Chemo-immunotherapy; Predictive biomarker; Case report
Core Tip	The first-line standard treatment for advanced intrahepatic cholangiocarcinoma has been PD-L1 antibody combined with GemCis therapy, but the median overall survival time still could not break 1 year. However, this patient achieved cCR after second-line treatment with paclitaxel combined with PD-1 antibody and has survived for more than 32 mo. And we performed genetic testing of tissue specimens and found that this patient was without known predictive biomarkers related to immunotherapy efficacy but with BRCA1, KRAS and NTRK3 mutation, and whether there is a therapeutic efficacy correlation deserves further exploration.
Publish Date	2022-11-08 07:44
Citation	He MY, Yan FF, Cen KL, Shen P. Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature. World J Clin Cases 2022; 10(32): 11889-11897
URL	https://www.wjgnet.com/2307-8960/full/v10/i32/11889.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i32.11889

Full Article (PDF)	WJCC-10-11889.pdf
Full Article (Word)	WJCC-10-11889.docx
Manuscript File	78099_Auto_Edited-JLW.docx
Answering Reviewers	78099-Answering reviewers.pdf
Audio Core Tip	78099-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	78099-Conflict-of-interest statement.pdf
Copyright License Agreement	78099-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	78099-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	78099-Language certificate.pdf
Peer-review Report	78099-Peer-review(s).pdf
Scientific Misconduct Check	78099-Bing-Liu GL-2.png
Scientific Editor Work List	78099-Scientific editor work list.pdf